Scholar Rock Holding Corp

SRRKNASDAQ · USD
48.63USD0.00 (+0.05%)
129

Scholar Rock Holding Corp (SRRK) Option Chain

As of September 24, 2026, Scholar Rock Holding Corp is trading at $48.63, a +0.05% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 54.7%. IV Rank is 11%.

Read more

Tracking the SRRK option chain helps you see every strike and expiry on Scholar Rock Holding Corp in one view, so you can quickly identify the contracts that fit your thesis and your risk. Scholar Rock Holding Corp's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of SRRK options activity at a glance. Use our scanner to monitor the SRRK option chain in real time and filter for the SRRK options trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For SRRK stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the SRRK option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where SRRK stock options are being actively traded and where they are not.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis.

The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Scholar Rock Holding Corp's full chain across every expiry, highlights the most liquid strikes, and lets you screen SRRK options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of SRRK stock options — let the full option chain come to you, pre-filtered and ready to trade.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile41.67% Neutral
  • Market cap (M$)5,922
  • 52 weeks high-21.26%
  • 52 weeks low79.65%
  • Analyst recommendationStrong Buy
    1.11
  • Target price$69.12
    42.13% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-13
  • P/E—
  • Future P/E—
  • EPS (ttm)-3.45
  • EPS growth next 5 years27.03%

As of September 24, 2026

2026-10-16
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
5.761902.028.639.5011.8040.00-19.760.100.350.000.238010994.24
24.0111522.573.635.007.4045.00-9.730.601.000.000.80052575.99
52.86429512.780.002.253.3050.00+0.302.102.851.371.11072347.14
78.08440331.050.000.801.3055.00+10.334.506.606.37-0.8207121.92
92.18612670.350.000.200.5060.00+20.369.4011.1011.37-1.120297.82

As of September 24, 2026

Scan the full option chain in one place

Browse the full SRRK option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.

Start your 14-day free trial